16 Bit is a healthcare technology company focused on creating AI-driven software as a medical device. Their key products, Rho and Physis, utilize advanced algorithms to improve osteoporosis screening and pediatric bone age assessment, respectively. With a value-based model of care, they aim to enhance healthcare quality and accessibility while increasing revenue for healthcare providers. The company has received FDA and Health Canada approvals, showcasing its market position and traction in the healthcare sector, impacting millions of lives through innovative solutions.

20/20 Optim Eyes Technologies is a biotechnology spin-out from McMaster University in Hamilton, Ontario, Canada, focused on developing a transformative drug delivery system for mucosal applications, particularly eye drops. Their patented Micelle Technology aims to improve the dosing regimen for glaucoma and dry eye diseases, shifting from twice daily to once or twice weekly, thereby enhancing patient comfort, compliance, and clinical outcomes. This innovative approach positions them strongly in the biotechnology market, targeting significant improvements in treatment efficacy and patient quality of life.

A.I. VALI analyzes physicians' voices during procedures in real-time using Machine Learning (ML) and Deep Learning (DL) techniques, as well as data obtained from medical imaging such as endoscopy video footage and tissue biopsy specimens. The AI is modular. AIDREA(TM) is a global platform that provides clients with accurate, reproducible, and inexpensive real-time analysis. AIDREA(TM) has a significant impact on the quality of analysis in the early diagnosis of diseases such as cancer, allowing for the most tailored treatment approach.

Able Innovations is advancing the quality of care, efficiency, and safety in healthcare through user-centric, robotic innovation. Their ALTA Platform® utilizes smart sensors and AI algorithms to facilitate safe and easy patient transfers, allowing a single user to manage transfers at the push of a button. The company is focused on eliminating physical strain on healthcare staff while ensuring patient dignity and comfort during transfers. With a mission driven by empathy and innovation, Able Innovations is positioned to redefine patient handling standards in the healthcare industry.

ACD/Labs develops and commercializes informatics solutions tailored for chemical, biochemical, and pharmaceutical R&D, serving a global client base across various industries. With over 30 years of experience, their software enhances research efficiency, collaboration, and data management, making them a leader in analytical data handling and chemical intelligence. Their products, including the Spectrus and Percepta platforms, are designed to meet the unique needs of R&D teams, ensuring they can innovate faster and make data-driven decisions. ACD/Labs is committed to sustainability and has a strong presence in over 99 countries, with a significant portion of the world's top pharmaceutical companies relying on their solutions.

Ace Age is a healthcare technology company focused on improving health outcomes for the elderly through innovative products. Their flagship product, Karie, is a personal health companion that automates medication management by organizing, scheduling, and dispensing pills with a simple one-button control. This device addresses the critical issue of medication non-adherence, which costs the US healthcare system $290 billion annually. By enabling patients to manage their medications independently, Karie enhances patient autonomy and reduces the burden on caregivers. The company has demonstrated significant traction, including a pilot study showing a 300% increase in medication adherence. Ace Age is positioned to make a substantial impact in the healthcare technology market, particularly for aging populations.

Acorn Biolabs is a personalized regenerative medicine company that offers a non-invasive solution for preserving individuals' own stem cells through follicle collection and cryopreservation. This innovative approach allows for the creation of personalized stem cell-based treatments, leveraging the power of the body's own cells to combat aging and promote recovery from injuries and diseases. With a focus on the future of regenerative medicine, Acorn Biolabs positions itself in a rapidly growing market, supported by a significant number of active clinical trials and an expected market value of $26 billion by 2026. The company aims to provide long-term access to preserved cells for various therapeutic applications, making it a unique player in the healthcare technology space.

Aiim Sense develops portable brain scanners to transform expensive head scans into real-time monitoring and preventative care at the patient’s bedside. This innovative approach aims to improve stroke management by making diagnostic procedures more accessible and cost-effective, thereby enhancing patient outcomes. The company's technology is designed to enable early diagnosis of strokes, positioning Aiim Sense as a significant player in the medical technology field. Their commitment to changing the stroke management paradigm is reflected in their active participation in medical technology events and collaborations to bring their lifesaving solutions to healthcare providers.

Allarta Life Science is a pre-clinical regenerative medicine company based in Hamilton, Ontario, Canada, specializing in the development of next-generation biomaterials for immune-privileged delivery of cells, stem cells, and biologics. Their proprietary platform technology aims to overcome immune rejection and prevent cell escape, with a focus on curative cell therapies, particularly for type 1 diabetes. Founded in 2019 by leading researchers in polymer science, Allarta has built a diverse team and an extensive network of collaborators, positioning itself as a key player in the regenerative medicine market.

AmacaThera is a clinical-stage biotechnology company specializing in the development of a unique injectable hydrogel platform that provides localized, sustained drug delivery. This innovative approach aims to improve patient outcomes across various therapeutic areas, including post-surgical pain management and cancer treatment. The company is positioned at the intersection of biomaterials and pharmaceuticals, leveraging advanced science to address significant healthcare challenges. With a strong team of experts and a focus on accountability and transparency, AmacaThera is poised to make a meaningful impact in the biotechnology sector.

Arrayus Technologies is a fast-growing medical technology company that is ushering in a new era of non-invasive cancer therapy.

Aspect Biosystems is a Canadian biotechnology company creating bioprinted tissue therapeutics to transform how we treat disease. Our bold team of innovators and entrepreneurs have joined us from all over the globe to create a new class of regenerative medicine and work towards a future where our bioprinted tissues are used to save lives and make people healthier. We are endlessly curious and wildly passionate about what we do. Every person on our team is a key contributor to our success and is eager to roll up their sleeves to make a difference in the ever-changing world of biotech. If you are committed to making a real impact and accelerating the development of life-changing therapies, we want to hear from you! At Aspect Biosystems, we celebrate diversity and are committed to creating an inclusive environment for all employees. All aspects of employment including the decision to hire, promote, discipline, or terminate, will be based on merit, competence, performance, and business needs. We do not discriminate on the basis of race, colour, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, provincial, or local law.